let's ask jeff meacham you have to think through the hard questions like this what answershave you come i would say to sustain the valuations we are at given unprecedented demand my guess is that you'll see a little bit more of a decline next year and then by the time of 2023 to 2025 i would sadie min misdemand and th >>> and this technology of the future, what would you say in response >> you know, we have an underperform on moderna. it's not that we are cheering for covid. it is literally a function of valuation. i get it the company did a great job during the covid development of their vaccine. but it just takes a lot of time. their cmd product, their flu product. it will take time to work through the clinical trial process. a lot of the vaccine makers i think it is going to be very difficult to really translate the recent benefit into long term benefit. >> you like lily and vir why? >> there are other things going on portfolios and pipelines lily have a great diabetes business up and commerce in the alzheimer's field. lots of things going on in terms of inflammation. their covid ant